Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
AQST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.12 - $5.80
Previous CloseN/A
Volume606.88K
Average Volume (3M)2.03M
Market Cap
$598.82M
Enterprise Value$394.49M
Total Cash (Recent Filing)$60.54M
Total Debt (Recent Filing)$126.26M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 10, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding120,973,630
10 Day Avg. Volume3,174,934
30 Day Avg. Volume2,028,850
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue8.94
Enterprise Value/Gross Profit14.63
Enterprise Value/Ebitda-8.82
Forecast
1Y Price Target
$9.00Price Target Upside78.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Financial PositionThe high quality of the investor syndicate signals institutional investor belief in Anaphylm and Aquestive's long-term prospects.
Market PotentialAnaphylm has the potential to be the first and only FDA-approved, non-invasive, orally delivered epinephrine product for severe allergic reactions.
Regulatory ApprovalThe FDA's decision to waive the advisory committee meeting is a meaningful risk-mitigating factor, boosting investor confidence in a favorable Anaphylm approval decision.
Bears Say
Financial OverhangAn $85M underwritten equity offering of 21.25M shares has been priced at $4.00 per share, which removes a financial overhang that has weighed on the stock.
Market CompetitionDespite the inherent variability of epinephrine, Anaphylm's ability to reach peak absorption in only 12 mins (Epipen: 20 mins; Neffy: 30 mins) with therapeutic blood concentrations in 5 minutes is reassuring.
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $2.12 and its highest was $5.80 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Aquestive Therapeutics’s market cap is $598.82M.
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Nov 10, 2025 which is in 57 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.167 by $0.027.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 120,973,630 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.167. Following the earnings report the stock price went down -2.073%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Currently, no hedge funds are holding shares in AQST
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (78.22% Upside)
$9.00 (78.22% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.98%
12-Months-Change
Fundamentals
Return on Equity
77.48%
Trailing 12-Months
Asset Growth
-20.33%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST Company Deck
AQST Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the development and pre-launch activities for Anaphylm, indicating promising market expansion opportunities. However, financial challenges, including revenue decline and increased net loss, along with market access barriers, present notable concerns.View all AQST earnings summariesAQST Stock 12 Month Forecast
Average Price Target
$9.00
▲(78.22% Upside)
Technical Analysis
Emergent Biosolutions
―
Lifecore Biomedical
―
Rockwell Med
―
Esperion
―
Journey Medical Corp
―
Ownership Overview
13.63% Insiders
6.43% Mutual Funds
19.22% Other Institutional Investors
52.88% Public Companies and
Individual Investors